In this work the cellular internalization and the intracellular effects of (2-hydroxypropyl)-beta (HPBCD) and random methyl-beta cyclodextrin (RAMEB) on Caco-2 intestinal epithelial cells and on HeLa cervix epithelioid carcinoma cell line were investigated [1,2]. The cellular internalization of fluorescein- (FITC) and rhodamine- (Rho) labeled HPBCD was examined by fluorescence microscopy and flow cytometry. FITC and Rho labeled derivatives entered the cells, and localized in smaller or larger granules in the cytoplasm on both cell lines, however the major differences were revealed in the inhibition of their endocytosis. The possible activation of the NF-κB pathway was investigated by fluorescence microscopy and the nuclear translocation of the p65 subunit was monitored. Cyclodextrin pretreatment did not activate this inflammatory pathway on Caco-2 and HeLa cells. The cyclodextrins effects on autophagy were tested qualitatively and quantitatively. In both cell lines, after HPBCD and RAMEB treatment, formation of the autophagosomes did not increase compared to the control sample. The lysosomes in the cells were examined by fluorescence microscopy. Significant amount of cyclodextrin could be detected in the lysosomes, but it can be noted that in Caco-2 cells larger lysosomal vesicles with higher cyclodextrin content than in HeLa cells. The main differences between the cellular effects of cyclodextrins on Caco-2 and HeLa cells are summarized in the table below.
 Rusznyák Á, Palicskó M, Malanga M, Fenyvesi É, Szente L, Váradi J, Bácskay I, Vecsernyés M, Réti-Nagy KS, Vasvári G, Haimhoffer Á, Fenyvesi F. Cellular Effects of Cyclodextrins: Studies on HeLa Cells. Molecules. 2022 Feb 28;27(5):1589. doi: 10.3390/molecules27051589.
 Rusznyák Á, Malanga M, Fenyvesi É, Szente L, Váradi J, Bácskay I, Vecsernyés M, Vasvári G, Haimhoffer Á, Fehér P, Ujhelyi Z, Nagy B Jr, Fejes Z, Fenyvesi F. Investigation of the Cellular Effects of Beta- Cyclodextrin Derivatives on Caco-2 Intestinal Epithelial Cells. Pharmaceutics. 2021 Jan 25;13(2):157. doi: 10.3390/pharmaceutics13020157.